Nuvalent News

Nuvalent Analyst Ratings

BenzingaApr 17 07:53 ET

Nuvalent Analyst Ratings

BenzingaApr 1 10:56 ET

Nuvalent Analyst Ratings

BenzingaMar 6 10:57 ET

Nuvalent Analyst Ratings

BenzingaFeb 28 09:17 ET

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)

TipRanksFeb 27 16:40 ET

Analysts' Top Healthcare Picks: Privia Health Group (PRVA), Nuvalent (NUVL)

TipRanksFeb 27 13:40 ET

Nuvalent Analyst Ratings

BenzingaFeb 23 05:48 ET

Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating

MT NewswiresFeb 12 08:58 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nuvalent (NUVL), NewAmsterdam Pharma Company (NAMS) and Marinus (MRNS)

TipRanksJan 9 01:40 ET

Hold Rating on Nuvalent Continues: Evaluating the Potential of NVL-655 and Anticipated Market Shifts

TipRanksNov 16, 2023 07:17 ET

TD Cowen Keeps Their Buy Rating on Nuvalent (NUVL)

TipRanksNov 14, 2023 12:16 ET

Piper Sandler Remains a Buy on Nuvalent (NUVL)

TipRanksOct 20, 2023 07:19 ET

BMO Capital Maintains Outperform on Nuvalent, Raises Price Target to $79

BenzingaOct 19, 2023 11:49 ET

Nuvalent Analyst Ratings

BenzingaOct 19, 2023 11:47 ET

Nuvalent (NUVL) Gets a Buy From Stifel Nicolaus

TipRanksOct 18, 2023 22:05 ET

Promising Performance of Nuvalent's NVL-655 and Its Potential Impact on ALK+ NSCLC Treatment: A Buy Recommendation

TipRanksOct 16, 2023 07:26 ET

Wedbush Raises Nuvalent Price Target to $74 From $65, Maintains Outperform Rating

MT NewswiresOct 13, 2023 11:54 ET

JPMorgan Adjusts Price Target on Nuvalent to $68 From $51, Maintains Overweight Rating

MT NewswiresOct 5, 2023 11:00 ET

Nuvalent Analyst Ratings

BenzingaOct 5, 2023 10:52 ET

Promising Future for Nuvalent: Novel ALK-Selective Inhibitor NVL-655 Bolsters Buy Rating and Increases Target Price

TipRanksOct 5, 2023 07:25 ET